Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM — REDWOOD-HCM

Hypertrophic Cardiomyopathy (HCM) Clinical Trial

Official title:
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy

Status Completed

Clinical Trial Summary

This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cardiomyopathies
Cardiomyopathy, Hypertrophic
Hypertrophic Cardiomyopathy (HCM)
Hypertrophy

Clinical Trial Details

NCT number	NCT04219826
Study type	Interventional
Source	Cytokinetics
Contact
Status	Completed
Phase	Phase 2
Start date	January 10, 2020
Completion date	February 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00753233` - Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy	N/A
Completed	`NCT01623245` - Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Active, not recruiting	`NCT06372457` - COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Enrolling by invitation	`NCT04189822` - Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
Enrolling by invitation	`NCT02413450` - Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias